Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pharmaceutical Sales — China share of Pharmaceutical revenue (%) (%)
Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales)
Latest, FY2025
3.1%
Period ended Dec 31, 2025
Change on a year earlier
-6.3 pts
9.4% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pharmaceutical Sales — China share of Pharmaceutical revenue (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.1% | -6.3 pts | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 9.4% | -3.1 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 12.5% | +2.7 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 9.8% | -0.2 pts | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 10.0% | +2.7 pts | Form 8-K (tm235007d1_ex99-1.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 7.3% | -0.2 pts | Form 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗ |
| FY2019 | Dec 31, 2019 | 7.5% | +0.8 pts | Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗ |
| FY2018 | Dec 31, 2018 | 6.7% | – | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
Cite this data
StockData. (2026). Merck Pharmaceutical Sales — China share of Pharmaceutical revenue (%) (%), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma_geo_china_share
See every metric in the Merck KPI table. Data updated Oct 26, 2026.